Matches 1 - 50 out of 110 1 2 3 >


Match Document Document Title
US20140031280 METHODS FOR PREVENTING AND TREATING POST-TRAUMATIC STRESS DISORDER (PTSD)  
Methods for preventing and/or treating symptoms of Post-Traumatic Stress Disorder (PTSD) are provided. The preferred method comprises administration of an effective amount of insulin to the upper...
US20140349926 FORMULATIONS FOR THE TREATMENT OF DIABETES  
Disclosed is a formulation for parenteral administration comprising insulin that comprises a pH memory between 1 to 4 or between 6 to 8 and an aprotic polar solvent, wherein the insulin is...
US20130261051 Treating Diabetes Melitus Using Insulin Injections Administered With Varying Injection Intervals  
The present invention relates to methods for treatment of a condition or disease where administration of insulin will be of benefit, comprising administering, to a patient in need thereof,...
US20110288013 GLYCEMIC CONTROL FOR REDUCTION OF CARDIOVASCULAR DISEASE RISK IN DIABETIC PATIENTS EXPRESSING HAPTOGLOBIN 2-2  
This invention relates to methods of reducing risk of developing cardiovascular complications in diabetic patients. Specifically, the invention relates to the use of haptoglobin genotyping for...
US20150164999 Long-Acting Formulations of Insulin  
The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.
US20150157735 PROTOZOAN VARIANT-SPECIFIC SURFACE PROTEINS (VSP) AS CARRIERS FOR ORAL DRUG DELIVERY  
The invention provides compositions for oral delivery and methods of treatment using VSP carriers, such as Giardia sp. variable surface proteins (VSP), to deliver therapeutic agents. VSP drug...
US20100099601 FIBRILLATION-RESISTANT INSULIN AND INSULIN ANALOGUES  
A fibrillation-resistant insulin analogue may be a single-chain insulin analogue or a physiologically acceptable salt thereof, containing an insulin A chain sequence or an analogue thereof and an...
US20150111819 TREATMENT FOR COMORBID DIABETES WITH CHRONIC KIDNEY DISEASE  
The present invention relates to an improved method for treating diabetes wherein the improvement comprises administering a PEGylated insulin compound to a patient having moderate to severe...
US20150119323 Stable Formulation of Insulin Glulisine  
An aqueous pharmaceutical formulation comprising 200-1000 U/mL of insulin glulisine.
US20120122775 Use of Ultrarapid Acting Insulin  
Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid...
US20070225210 Therapeutic vaccine compositions for the treatment of type 1 diabetes  
The invention concerns therapeutic vaccine compositions that comprise modified Insulin B chain components suitable for use as immunogenic agents for treatment and prevention of Type 1 Diabetes.
US20050171008 Monomeric insulin  
This invention provides a novel monomeric insulin B27K-DTrI, B27K-destripeptide-Insulin) its composition and the method of preparation therefore. Highly pure B27K-DTrI-Insulin is monomeric...
US20150005231 HALOGEN-STABILIZED INSULIN  
An insulin analogue comprises a B-chain polypeptide incorporating a halogenated phenylalanine at position B24, B25 or B26. The halogenated phenylalanine may be ortho-monofluoro-phenylalanine,...
US20110166064 HALOGEN-STABILIZED INSULIN  
An insulin analogue comprises a B-chain polypeptide incorporating a halogenated phenylalanine at position B24, B25 or B26. The halogenated phenylalanine may be ortho-monofluoro-phenylalanine,...
US20140038888 PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS  
The invention relates to a pharmaceutical composition comprising 1.a and/or 1.b according to claim 1 in combination with at least one second therapeutic agent 2 which is suitable in the treatment...
US20120277149 PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS  
The invention relates to a pharmaceutical composition comprising 1.a and/or 1.b according to claim 1 in combination with at least one second therapeutic agent 2 which is suitable in the treatment...
US20120071402 Protease Stabilized, Pegylated Insulin Analogues  
Novel PEGylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H. The PEGylation...
US20110230402 TREATING DIABETES MELITUS USING INSULIN INJECTIONS WITH LESS THAN DAILY INJECTION FREQUENCY  
The present invention relates to an insulin derivative for the treatment of a condition or disease where administration of insulin will be of benefit, comprising administering, to a patient in...
US20060217290 Insulin analogs having protracted time action  
The present invention provides the insulin analog A0Arg A21Gly B31Arg B32Arg, which provides a protracted, even basal duration of action. The present invention also provides a method of treating...
US20060258561 Novel NPH insulin preparations  
This invention relates to NPH-insulin (crystalline preparations) that are prepared in the presence of certain high-affinity ligands for the HisB10 Zn2+-sites of the R-state insulin hexamer....
US20140128319 INSULIN ANALOGUES CONTAINING PENTA-FLUORO-PHENYLALANINE AT POSITION B24  
An insulin analogue comprises a B-chain polypeptide incorporating a halogenated phenylalanine at position B24, B25 or B26. The halogenated phenylalanine may be ortho-monofluoro-phenylalanine,...
US20120021978 COMBINATION OF AN INSULIN AND A GLP-1-AGONIST  
The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist.
US20140274888 CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY  
Conjugates which comprise a drug and a ligand which includes a first saccharide; wherein the conjugate is characterized in that, when the conjugate is administered to a mammal, at least one...
US20140323398 ULTRA-CONCENTRATED RAPID-ACTING INSULIN ANALOGUE FORMULATIONS  
A pharmaceutical formulation comprises insulin having a variant insulin B-chain polypeptide containing an ortho-monofluoro-Phenylalanine substitution at position B24 in combination with a...
US20140315798 CHEMICALLY AND THERMODYNAMICALLY STABLE INSULIN ANALOGUES AND IMPROVED METHODS FOR THEIR PRODUCTION  
The subject matter of this invention is directed towards chemically and thermodynamically stable single-chain insulin (SCI) analogues that are resistant to deamidation and fibrillation. The...
US20150111820 NOVEL USE OF INSULIN DERIVATIVES  
This invention relates to insulin derivatives having long duration of action. The insulin derivatives have been found to be useful for the treatment of diabetes, and in particular for less...
US20060019874 Cation complexes of insulin compund conjugates, formulation and uses thereof  
The invention provides a complex including a cation and an insulin compound conjugate. The insulin compound conjugate includes insulin compound, such as human insulin or an analog thereof,...
US20060148676 Polyamino acid-based particle insulin formulation  
This invention relates to dual-release formulations of insulin comprising polyamino acid particles and insulin, and a method of preparing such formulations
US20120184487 INSULIN DERIVATIVES  
The novel insulin derivates delivers, after administration to humans, insulin as a function of the glucose concentration in the tissue.
US20120035103 METHOD FOR ADMINISTRATION OF INSULIN AND PHARMACEUTICAL COMPOSITION THEREOF  
The present invention provides pharmaceutical compositions including alkylglycosides admixed with at least one of fast-acting and long-acting insulin analogs for treatment of disorders, such as...
US20140303076 NON-STANDARD INSULIN ANALOGUES  
An insulin analogue comprises a B-chain polypeptide containing a cyclohexanylalanine substitution at position B24 and optionally containing additional amino-acid substitutions at positions A8,...
US20120165251 Diabetes therapy  
The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a DPP-4 inhibitor and a long-acting insulin. The invention...
US20070190159 Polyamino acid-based insulin preparation  
This invention relates to sustained release preparations of insulin comprising poly-amino acid particles, insulin and one or more preservative agents, and a method of preparing such preparations.
US20110077196 NON-STANDARD INSULIN ANALOGUES  
An insulin analogue comprises a B-chain polypeptide containing at least one alteration selected from a methylated phenylalanine substitution at position B24 and an addition of two amino acids to...
US20080171694 Pharmaceutical Formulation Comprising Crystalline Insulin and Dissolved Insulin  
The invention provides a pharmaceutical formulation and a method for preparing the formulation.
US20050014679 Insulin molecule having protracted time action  
The present invention provides an insulin molecule that provides a protracted, even basal duration of action. The insulin molecule comprises a modification at the N-terminus of the A-chain,...
US20080146492 Insulin production methods and pro-insulin constructs  
Novel pro-insulin having specific amino acid and/or nucleic acid modifications suitable for improved methods of insulin production are provided. Novel and highly efficient processes for preparing...
US20150126439 PHARMACEUTICAL COMPOSITION  
A combination comprising at least a first insulin-like compound and a second insulin-like compound for treating a condition or a disease in a subject in need thereof where administration of...
US20100143374 DIAGNOSTIC AND THERAPEUTIC TARGET FOR AUTOIMMUNE DISEASES AND USES THEREOF  
Described is the identification of ZnT8 as an autoantigen target in type I autoimmune diabetes (T1D), other autoimmune disease, and other diabetes-linked diseases and conditions. Also described...
US20120094903 COMPOSITIONS FOR INTRANASAL DELIVERY OF HUMAN INSULIN AND USES THEREOF  
What is described is a pharmaceutical formulation for intranasal delivery of insulin to a patient, comprising an aqueous mixture of human insulin, a solubilizing agent, a surface active agent, and...
US20110105392 Pegylated Insulin Lispro Compounds  
The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene...
US20120183616 LONG ACTING INSULIN COMPOSITION  
The present invention relates to a pharmaceutical composition comprising an insulin compound in a concentration that is sufficient to maintain a therapeutically effective level of the insulin...
US20130331320 FAST-ACTING INSULIN IN COMBINATION WITH LONG-ACTING INSULIN  
Insulin preparations comprising a long-acting insulin compound, a fast-acting insulin compound, a nicotinic compound and an amino acid.
US20120252724 INSULIN PREPARATIONS CONTAINING METHIONINE  
The invention relates to an aqueous pharmaceutical formulation having insulin, an insulin analog, or an insulin derivative, and methionine; and to the production thereof, to the use thereof for...
US20100009923 Antigens Targeted by Pathogenic Al4 T Cells in Type 1 Diabetes and Uses Thereof  
Provided are oligopeptide antigens to A14-like T cells, and mouse proteins comprising those antigens. The oligopeptide antigens comprise the amino acid sequence XX(I/D/F/L)ENY(I/L)(E/W/Y)(L/M) or...
US20150005230 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY  
Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system...
US20130196906 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY  
Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system...
US20060019873 Cation complexes of insulin compound conjugates, formulations and uses thereof  
An insulin compound coupled to a modifying moiety having a formula: —X—R1—Y-PAG-Z-R (Formula VI) where, X, Y and Z are independently selected linking groups and each is optionally present, and X,...
US20060069013 Pharmaceutical preparations comprising acid-stabilised insulin  
Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer that are capable of prolonging the action of insulin preparations are disclosed.
US20050065066 Stabilised insulin compositions  
The present invention provides pharmaceutical compositions comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer. The resulting preparations have improved...

Matches 1 - 50 out of 110 1 2 3 >